You would think that it would be a "No Brainer" for a larger company to partner up, and get that phase three trial done, for them get license for the new standard of care for NASH/MASH. Between our phase two results, and further confirmation from the lab studies, this indication should be a low risk/high reward investment.

https://clinicaltrials.gov/study/NCT04521114?...amp;rank=1